Share on StockTwits

DexCom (NASDAQ:DXCM) SVP Andrew K. Balo sold 10,000 shares of DexCom stock on the open market in a transaction dated Friday, July 11th. The shares were sold at an average price of $35.93, for a total value of $359,300.00. Following the transaction, the senior vice president now directly owns 159,099 shares in the company, valued at approximately $5,716,427. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of DexCom (NASDAQ:DXCM) traded down 1.59% during mid-day trading on Tuesday, hitting $36.41. The stock had a trading volume of 560,197 shares. DexCom has a 1-year low of $21.76 and a 1-year high of $49.83. The stock has a 50-day moving average of $37.36 and a 200-day moving average of $38.2. The company’s market cap is $2.728 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.09. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. On average, analysts predict that DexCom will post $-0.33 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on DXCM shares. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, June 27th. They now have a $42.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of DexCom from $38.00 to $40.00 in a research note on Tuesday, June 17th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Friday, May 2nd. They now have a $44.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $39.60.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.